Browse GSC

Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00046 Homeobox domain
Function

Regulates chordin (CHRD). May play a role in spatial programing within discrete embryonic fields or lineage compartments during organogenesis. In concert with NKX3-2, plays a role in defining the structural components of the middle ear; required for the development of the entire tympanic ring (By similarity). Probably involved in the regulatory networks that define neural crest cell fate specification and determine mesoderm cell lineages in mammals.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001708 cell fate specification
GO:0001837 epithelial to mesenchymal transition
GO:0003002 regionalization
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007517 muscle organ development
GO:0009953 dorsal/ventral pattern formation
GO:0014029 neural crest formation
GO:0014033 neural crest cell differentiation
GO:0014034 neural crest cell fate commitment
GO:0014036 neural crest cell fate specification
GO:0016055 Wnt signaling pathway
GO:0021532 neural tube patterning
GO:0021904 dorsal/ventral neural tube patterning
GO:0021915 neural tube development
GO:0023019 signal transduction involved in regulation of gene expression
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030900 forebrain development
GO:0042471 ear morphogenesis
GO:0042474 middle ear morphogenesis
GO:0043583 ear development
GO:0045165 cell fate commitment
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048644 muscle organ morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0048865 stem cell fate commitment
GO:0048866 stem cell fate specification
GO:0060485 mesenchyme development
GO:0090596 sensory organ morphogenesis
GO:0198738 cell-cell signaling by wnt
Molecular Function GO:0001085 RNA polymerase II transcription factor binding
GO:0001103 RNA polymerase II repressing transcription factor binding
GO:0008134 transcription factor binding
GO:0070491 repressing transcription factor binding
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GSC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GSC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GSC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7460.0179
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0230.0604
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5440.25
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.560.0139
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.90.231
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-3.3940.0575
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.280.634
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5780.569
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3550.553
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9670.236
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0730.811
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GSC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GSC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GSC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GSC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GSC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GSC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GSC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGSC
Namegoosecoid homeobox
Aliases Homeobox protein goosecoid
Chromosomal Location14q32.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GSC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.